| Oct 15 |
Sutro Biopharma: Post ESMO Selloff, Does Their Strategy In FRα Remain Viable?
|
| Oct 10 |
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
|
| Sep 23 |
Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology
|
| Sep 20 |
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
| Sep 14 |
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
|
| Sep 11 |
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024
|
| Aug 26 |
Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why
|
| Aug 23 |
Sutro Biopharma commences Phase II trial of luvelta for lung cancer
|
| Aug 22 |
Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
|
| Aug 15 |
Companies Like Sutro Biopharma (NASDAQ:STRO) Are In A Position To Invest In Growth
|
